多发性骨髓瘤患者使用卡非佐米相关的收缩功能障碍。 - Suppr

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma.

作者信息

Jain Tania, Narayanasamy Hemalatha, Mikhael Joseph, Reeder Craig B, Bergsagel P Leif, Mayo Angela, Stewart A Keith, Mookadam Farouk, Fonseca Rafael

机构信息

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.

Division of Cardiology, Mayo Clinic, Phoenix, AZ, USA.

出版信息

Blood Cancer J. 2017 Dec 13;7(12):642. doi: 10.1038/s41408-017-0026-7.

DOI:10.1038/s41408-017-0026-7

PMID:29234003

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5802500/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620e/5802500/4b03481ce85d/41408_2017_26_Fig1_HTML.jpg

相似文献

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma.

Blood Cancer J. 2017 Dec 13;7(12):642. doi: 10.1038/s41408-017-0026-7.

Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.

Intern Med. 2019 Jun 1;58(11):1577-1581. doi: 10.2169/internalmedicine.2194-18. Epub 2019 Feb 1.

A case of acute liver failure due to carfilzomib in multiple myeloma.

J Clin Pharm Ther. 2018 Dec;43(6):918-920. doi: 10.1111/jcpt.12741. Epub 2018 Jul 3.

Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.

Oncology (Williston Park). 2013 Dec;27 Suppl 3:2-3.

Carfilzomib for the treatment of multiple myeloma.

Drugs Today (Barc). 2013 Mar;49(3):171-9. doi: 10.1358/dot.2013.49.3.1939264.

Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.

Eur J Pharmacol. 2018 Nov 5;838:85-90. doi: 10.1016/j.ejphar.2018.09.014. Epub 2018 Sep 7.

Carfilzomib-associated tumor lysis syndrome.

Pharmacotherapy. 2014 May;34(5):e34-7. doi: 10.1002/phar.1397. Epub 2014 Jan 4.

Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.

Cancer Med. 2021 Jan;10(1):70-78. doi: 10.1002/cam4.3568. Epub 2020 Nov 10.

Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.

High Blood Press Cardiovasc Prev. 2018 Jun;25(2):209-218. doi: 10.1007/s40292-018-0256-1. Epub 2018 Mar 26.

Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.

J Oncol Pharm Pract. 2017 Mar;23(2):152-156. doi: 10.1177/1078155215626788. Epub 2016 Jul 7.

引用本文的文献

Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system.

iScience. 2025 Jul 29;28(9):113228. doi: 10.1016/j.isci.2025.113228. eCollection 2025 Sep 19.

Short-Term Proteasome Inhibition: Assessment of the Effects of Carfilzomib and Bortezomib on Cardiac Function, Arterial Stiffness, and Vascular Reactivity.

Biology (Basel). 2024 Oct 21;13(10):844. doi: 10.3390/biology13100844.

Cardiovascular imaging in cardio-oncology.

Jpn J Radiol. 2024 Dec;42(12):1372-1380. doi: 10.1007/s11604-024-01636-x. Epub 2024 Aug 29.

Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

J Am Heart Assoc. 2021 Dec 21;10(24):e022247. doi: 10.1161/JAHA.121.022247. Epub 2021 Dec 7.

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States.

Front Cardiovasc Med. 2021 Sep 27;8:735466. doi: 10.3389/fcvm.2021.735466. eCollection 2021.

Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.

Leukemia. 2021 May;35(5):1418-1427. doi: 10.1038/s41375-021-01141-4. Epub 2021 Feb 15.

Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.

Cancer Med. 2021 Jan;10(1):70-78. doi: 10.1002/cam4.3568. Epub 2020 Nov 10.

Carfilzomib induced cardiotoxicity in a multiple myeloma patient.

Cardiooncology. 2020 Sep 7;6:17. doi: 10.1186/s40959-020-00074-8. eCollection 2020.

Oncocardiology: new challenges, new opportunities.

Herz. 2020 Nov;45(7):619-625. doi: 10.1007/s00059-020-04951-x.

Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.

Cancer. 2020 Feb 15;126(4):808-813. doi: 10.1002/cncr.32601. Epub 2019 Nov 13.

本文引用的文献

Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

Blood Adv. 2017 Feb 27;1(7):449-454. doi: 10.1182/bloodadvances.2016003269. eCollection 2017 Feb 28.

Management of Carfilzomib-Associated Cardiac Adverse Events.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):241-5. doi: 10.1016/j.clml.2016.01.008. Epub 2016 Feb 4.

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Blood Cancer J. 2016 Jan 15;6(1):e384. doi: 10.1038/bcj.2015.112.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.

Blood Cancer J. 2015 Jan 16;5(1):e272. doi: 10.1038/bcj.2014.93.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.

BMC Cancer. 2014 Dec 4;14:915. doi: 10.1186/1471-2407-14-915.

Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.

J Card Fail. 2015 Feb;21(2):138-44. doi: 10.1016/j.cardfail.2014.11.008. Epub 2014 Nov 26.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9.

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.

Curr Cardiol Rev. 2011 Nov;7(4):214-20. doi: 10.2174/157340311799960645.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献